<DOC>
	<DOCNO>NCT01838668</DOCNO>
	<brief_summary>This multicenter study conduct 2 part : The primary objective Part I study determine efficacy BG00012 ( dimethyl fumarate , DMF ) inflammatory brain magnetic resonance imaging ( MRI ) lesion activity ( Gadolinium-enhancing lesion ) compare placebo 4 scan perform Weeks 12 , 16 , 20 , 24 participant Relapsing Remitting Multiple Sclerosis ( RRMS ) include participant Asia-Pacific region . The secondary objective Part I study study population determine whether BG00012 , compare placebo 24 week , effective reduce cumulative number new Gadolinium-enhancing lesion Baseline Week 24 ; reduce number new newly enlarge T2 hyperintense lesion brain MRI scan Week 24 compare Baseline . The primary objective Part II ( open label ) study evaluate long-term safety profile BG00012 eligible participant Part I .</brief_summary>
	<brief_title>An Efficacy Safety Study BG00012 ( Dimethyl Fumarate ) Asian Subjects With Relapsing Remitting Multiple Sclerosis ( RRMS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Key Inclusion Criteria Part I : Must diagnosis RelapsingRemitting Multiple Sclerosis ( RRMS ) . Must baseline Expanded Disability Status Scale ( EDSS ) score 0.0 5.0 , inclusive . Key Inclusion Criteria Part II : â€¢ Subjects participate complete Part I per protocol . Key Other chronic disease immune system , malignancy , acute urologic , pulmonary , gastrointestinal disease . Pregnant nursing woman . NOTE : Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>